Medicaid
Covered (preferred drug)No additional clinical requirements are listed beyond the diagnosis.
Qualification pathways
You can qualify through any one of these.
Diabetic Kidney Disease - GLP-1 receptor agonist (no PA required)
All of:
- Ozempic (semaglutide) is listed as NO PA REQUIRED under Diabetic Kidney Disease - GLP-1 receptor agonist category
Policy note: Under the 'Diabetic Kidney Disease' section, Ozempic (semaglutide) is explicitly listed as a GLP-1 receptor agonist with NO PA REQUIRED. This is a separate formulary listing from the diabetes GLP-1 agonist section. No specific CKD severity criteria (eGFR, UACR) are stated for Ozempic in this section - it appears to be covered without PA for diabetic kidney disease. Kerendia (finerenone) in the same section requires PA and specifies eGFR ≥25 and UACR ≥30 mg/g criteria, but those criteria apply to Kerendia, not Ozempic.
Policy effective April 1, 2026 · verified June 3, 2026 · source: PDL-2026.4.pdf